DEFB112

Across TCGA pan-cancer cohorts, DEFB112 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DEFB112 data layer compared with 9 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher DEFB112 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DEFB112 expression acts as an unfavorable survival marker.

BLCA, LUSC, and COAD are the cancer types where DEFB112 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.137	0.593	<.001	39	view →
LUSC	OS	Median	II,III,IV	0.200	0.634	.003	21	view →
COAD	DFS	Median	All	0.170	0.790	.002	15	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DEFB112–BLCA (OS)

Open the BLCA breakdown →